Mustafa Özgüroğlu

41.7k total citations · 9 hit papers
258 papers, 10.2k citations indexed

About

Mustafa Özgüroğlu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Mustafa Özgüroğlu has authored 258 papers receiving a total of 10.2k indexed citations (citations by other indexed papers that have themselves been cited), including 184 papers in Oncology, 157 papers in Pulmonary and Respiratory Medicine and 57 papers in Surgery. Recurrent topics in Mustafa Özgüroğlu's work include Cancer Immunotherapy and Biomarkers (69 papers), Lung Cancer Treatments and Mutations (55 papers) and Prostate Cancer Treatment and Research (54 papers). Mustafa Özgüroğlu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (69 papers), Lung Cancer Treatments and Mutations (55 papers) and Prostate Cancer Treatment and Research (54 papers). Mustafa Özgüroğlu collaborates with scholars based in Türkiye, United States and Japan. Mustafa Özgüroğlu's co-authors include Johann S. de Bono, Oliver Sartor, Kim N., Stéphane Oudard, Steinbjørn Hansen, Liji Shen, Gwénaëlle Gravis, Ivo Kocák, Dingwei Ye and I. Bodrogi and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Mustafa Özgüroğlu

247 papers receiving 10.1k citations

Hit Papers

Prednisone plus cabazitaxel or mitoxantrone for metastati... 2010 2026 2015 2020 2010 2017 2019 2019 2020 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
    2010 2.4k citations Johann S. de Bono, Stéphane Oudard et al. profile →
  2. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
    2017 1.4k citations Karim Fizazi, Nobuaki Matsubara et al. New England Journal of Medicine profile →
  3. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
    2019 891 citations Kim N., Neeraj Agarwal et al. New England Journal of Medicine profile →
  4. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
    2019 517 citations Karim Fizazi, Nobuaki Matsubara et al. profile →
  5. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
    2020 474 citations Maha Hussain, Joaquı́n Mateo et al. New England Journal of Medicine profile →
  6. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
    2018 336 citations Fabrice Barlési, David R. Spigel et al. profile →
  7. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
    2019 305 citations Ki Hyeong Lee, Luis Paz‐Ares et al. Journal of Thoracic Oncology profile →
  8. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study
    2021 285 citations Kim N., Simon Chowdhury et al. Journal of Clinical Oncology profile →
  9. LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2
    2024 37 citations J. Menezes, Mustafa Özgüroğlu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mustafa Özgüroğlu Türkiye 34 7.8k 4.5k 2.4k 2.3k 1.4k 258 10.2k
Gwénaëlle Gravis France 41 6.3k 0.8× 3.4k 0.8× 1.8k 0.7× 2.1k 0.9× 2.2k 1.5× 368 9.2k
Aude Fléchon France 33 4.9k 0.6× 2.6k 0.6× 1.6k 0.6× 1.5k 0.7× 1.8k 1.2× 273 7.7k
David Olmos United Kingdom 48 6.3k 0.8× 4.1k 0.9× 1.4k 0.6× 3.2k 1.4× 3.2k 2.2× 233 10.4k
Eleni Efstathiou United States 41 4.7k 0.6× 2.4k 0.5× 1.3k 0.5× 1.7k 0.8× 2.0k 1.4× 203 7.4k
Jorge A. García United States 43 6.2k 0.8× 2.1k 0.5× 1.4k 0.6× 2.4k 1.1× 2.6k 1.8× 213 8.1k
Arturo Molina United States 44 4.6k 0.6× 2.5k 0.6× 2.3k 1.0× 1.7k 0.8× 1.1k 0.7× 161 7.8k
Christine Théodore France 39 6.0k 0.8× 3.5k 0.8× 1.6k 0.7× 1.7k 0.8× 2.1k 1.4× 164 10.5k
A Płużańska Poland 28 8.3k 1.1× 6.3k 1.4× 1.4k 0.6× 2.9k 1.3× 3.2k 2.2× 65 11.6k
Lee S. Rosen United States 50 3.8k 0.5× 8.4k 1.9× 1.7k 0.7× 1.1k 0.5× 3.6k 2.5× 232 12.1k
Ugo De Giorgi Italy 51 4.7k 0.6× 3.8k 0.8× 1.1k 0.4× 2.4k 1.1× 2.3k 1.6× 489 9.0k

Countries citing papers authored by Mustafa Özgüroğlu

Since Specialization
Citations

This map shows the geographic impact of Mustafa Özgüroğlu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mustafa Özgüroğlu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mustafa Özgüroğlu more than expected).

Fields of papers citing papers by Mustafa Özgüroğlu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mustafa Özgüroğlu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mustafa Özgüroğlu. The network helps show where Mustafa Özgüroğlu may publish in the future.

Co-authorship network of co-authors of Mustafa Özgüroğlu

This figure shows the co-authorship network connecting the top 25 collaborators of Mustafa Özgüroğlu. A scholar is included among the top collaborators of Mustafa Özgüroğlu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mustafa Özgüroğlu. Mustafa Özgüroğlu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sen, G., et al.. (2025). Effects of immune related adverse events and corticosteroids on the outcome of patients treated with immune checkpoint inhibitors. Scientific Reports. 15(1). 6310–6310. 1 indexed citations
2.
3.
Arslan, Çağatay, Mert Başaran, İrfan Çiçin, et al.. (2024). Perceptions and Expectations: A Study on Prognostic Perception and Quality of Life in Patients With Metastatic Renal and Bladder Cancer. JCO Global Oncology. 10(10). e2400201–e2400201. 1 indexed citations
4.
Saad, Fred, Andrew J. Armstrong, Karina Vianna, et al.. (2024). Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial. European Urology Oncology. 7(6). 1394–1402. 7 indexed citations
5.
6.
7.
Cheng, Ying, David R. Spigel, Jian Fang, et al.. (2024). MA17.04 Patient-Reported Outcomes (PROs) With Consolidation Durvalumab Versus Placebo Following cCRT in Limited-Stage SCLC: ADRIATIC. Journal of Thoracic Oncology. 19(10). S124–S125. 1 indexed citations
8.
Powles, Thomas, Tibor Csőszi, Yohann Loriot, et al.. (2024). Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study. Clinical Genitourinary Cancer. 23(1). 102261–102261.
9.
10.
11.
Levy, Benjamin, Fabrice Barlési, Luis Paz‐Ares, et al.. (2022). Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO). Lung Cancer. 166. 107–113. 6 indexed citations
12.
13.
Çiçin, İrfan, Amel Mézlini, Slim Ben Ahmed, et al.. (2021). An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction. SHILAP Revista de lepidopterología. 18(1). 63–73. 2 indexed citations
14.
N., Kim, Simon Chowdhury, Anders Bjartell, et al.. (2021). Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. Journal of Clinical Oncology. 39(20). 2294–2303. 285 indexed citations breakdown →
15.
Hussain, Maha, Joaquı́n Mateo, Karim Fizazi, et al.. (2020). Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine. 383(24). 2345–2357. 474 indexed citations breakdown →
16.
Alva, Ajjai, Tibor Csőszi, Mustafa Özgüroğlu, et al.. (2020). LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361. Annals of Oncology. 31. S1155–S1155. 47 indexed citations
17.
Özgüroğlu, Mustafa, Kohei Shitara, Kyung-Woo Lee, et al.. (2020). 1459P Albumin as a simple criterion to reduce early mortality (EM) in gastric cancer (GC) trials. Annals of Oncology. 31. S915–S915. 1 indexed citations
18.
Elaidi, Réza, Mustafa Özgüroğlu, Hélène Gauthier, et al.. (2016). Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter Study. Clinical Genitourinary Cancer. 15(3). e469–e476. 8 indexed citations
19.
Öztürk, Mehmet Akif, et al.. (2014). Receptor Expression Discrepancy between Primary and Metastatic Breast Cancer Lesions. Oncology Research and Treatment. 37(11). 622–626. 9 indexed citations
20.
Öksüz, Didem Çolpan, et al.. (2012). UNUSUAL PRESENTATION OF CERVICAL CARCINOMA METASTASIS TO THE BREAST: A CASE REPORT AND REVIEW OF THE LITERATURE. SHILAP Revista de lepidopterología. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gwénaëlle Gravis Breakdown of academic impact, for papers by Aude Fléchon Breakdown of academic impact, for papers by David Olmos Breakdown of academic impact, for papers by Eleni Efstathiou Breakdown of academic impact, for papers by Jorge A. García Breakdown of academic impact, for papers by Arturo Molina Breakdown of academic impact, for papers by Christine Théodore Breakdown of academic impact, for papers by A Płużańska Breakdown of academic impact, for papers by Lee S. Rosen Breakdown of academic impact, for papers by Ugo De Giorgi
Rankless by CCL
2026